Patents by Inventor Robert C. Huebner
Robert C. Huebner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11932311Abstract: A vehicle assembly includes a cargo bed having a first and a second sidewall. A rail assembly is disposed on the first sidewall. The rail assembly is movable between an extended position and a retracted position relative to the first sidewall. An actuator system raises and lowers the rail assembly to move the rail assembly between the extended position and the retracted position.Type: GrantFiled: October 19, 2021Date of Patent: March 19, 2024Assignee: Ford Global Technologies, LLCInventors: Stuart C. Salter, David Brian Glickman, Paul Kenneth Dellock, Annette Lynn Huebner, Pietro Buttolo, Robert Walsh, Jacob Michael Haspiel, Joseph Ian Halaszynski
-
Patent number: 7960535Abstract: The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of Borrelia burgdorferi, which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of S. pneumoniae infection.Type: GrantFiled: November 16, 2009Date of Patent: June 14, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Edwin W. Ades, George M. Carlone, Barun K. De, Jacquelyn S. Sampson, Robert C. Huebner
-
Publication number: 20100260802Abstract: The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of Borrelia burgdorferi, which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of S. pneumoniae infection.Type: ApplicationFiled: November 16, 2009Publication date: October 14, 2010Inventors: Edwin W. Ades, George M. Carlone, Barun K. De, Jacquelyn S. Sampson, Robert C. Huebner
-
Patent number: 7635486Abstract: The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of Borrelia burgdorferi, which leader sequence is joined in translational reading frame with the psaA structural gene. The invention also provides methods of preparation of lipidated PsaA proteins and use of such proteins in immunological compositions. Also provided are vaccines comprising immunogenic lipidated PsaA proteins and methods of use of such vaccines in the prevention and treatment of S. pneumoniae infection.Type: GrantFiled: January 14, 1999Date of Patent: December 22, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Edwin W. Ades, George M. Carlone, Barun K. De, Jacquelyn S. Sampson, Robert C. Huebner
-
Patent number: 7235243Abstract: Immununological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: July 1, 2005Date of Patent: June 26, 2007Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Patent number: 7179596Abstract: The present invention provides a biological particle analogue, or biological analogue, that simulates a chosen biological organism or compound. The biological analogue includes a first portion that is not, in and of itself, recognized by the biological detection system, and a second portion, which provides the properties necessary for recognition by the detection system, carried by the first portion. The biological analogue is constructed in such a way as to include some important characteristics of the chosen biological organism or compound, while excluding other undesirable characteristics of the chosen biological organism or compound. The present invention is useful in testing a variety of biological detection systems.Type: GrantFiled: February 17, 2003Date of Patent: February 20, 2007Assignee: Sceptor Industries, Inc.Inventors: Andrew E. Page, Kelly L Brown, David S. Alburty, Robert C. Huebner
-
Patent number: 6984385Abstract: Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: March 12, 2002Date of Patent: January 10, 2006Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Publication number: 20040191770Abstract: The present invention provides a biological particle analogue, or biological analogue, that simulates a chosen biological organism or compound. The biological analogue includes a first portion that is not, in and of itself, recognized by the biological detection system, and a second portion, which provides the properties necessary for recognition by the detection system, carried by the first portion. The biological analogue is constructed in such a way as to include some important characteristics of the chosen biological organism or compound, while excluding other undesirable characteristics of the chosen biological organism or compound. The present invention is useful in testing a variety of biological detection systems.Type: ApplicationFiled: February 17, 2003Publication date: September 30, 2004Applicant: MIDWEST RESEARCH INSTITUTE, INC.Inventors: Andrew E. Page, Kelly L Brown, David S. Alburty, Robert C. Huebner
-
Patent number: 6538118Abstract: Heterologous lipidated proteins formed recombinantly are disclosed and claimed. The expression system can be E. coli. The heterologous lipidated protein has a leader sequence which does not naturally occur with the protein portion of the lipidated protein. The lipidated protein can have the Borrelia OspA leader sequence. The protein portion can be OspC, PspA, UreA, Ure B, or a fragment thereof. Methods and compositions for forming and employing the proteins are also disclosed and claimed.Type: GrantFiled: April 28, 1998Date of Patent: March 25, 2003Assignee: Connaught Laboratories, Inc.Inventors: Robert C. Huebner, Lorne F. Erdile, Donald J. Warakomski, Jr., Robert S. Becker, Maryann B. Gray, Derek J. Pyle
-
Publication number: 20020131983Abstract: Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: ApplicationFiled: March 12, 2002Publication date: September 19, 2002Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Patent number: 6451769Abstract: Disclosed is a vaccine against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding Borrelia OspA or OspB, and a DNA encoding a terminator. Disclosed too is an immunogenic composition against Lyme Disease or its causative agent Borrelia burgdorferi (sensu stricto or sensu lato) containing a plasmid comprising a DNA encoding a promoter for driving expression in a mammalian cell, DNA encoding a leader peptide for facilitating secretion/release of a prokaryotic protein sequence from a mammalian cell, a DNA encoding a Borrelia OspC, and a DNA encoding a terminator. And, methods for making and using such vaccines and the immunogenic composition are also disclosed.Type: GrantFiled: October 15, 1998Date of Patent: September 17, 2002Assignees: Pasteur Merieux Serums et Vaccins, Vical, Inc., The University of Texas SystemInventors: Robert C. Huebner, Jon A. Norman, Xiaowu Liang, Kristin R. Carner, Alan G. Barbour, Catherine J. Luke
-
Patent number: 6379675Abstract: Immunological compositions and methods for making and using them. The compositions contain at least one antigen and at least one lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immunogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: January 19, 1996Date of Patent: April 30, 2002Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann Gray, Karen S. Biscardi, Lorne F. Erdile, Bruno Guy
-
Patent number: 6251405Abstract: Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: June 7, 1995Date of Patent: June 26, 2001Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann B. Gray, Karen S. Biscardi
-
Patent number: 5846946Abstract: Plasmid DNA encoding at least one Borrelia genospecies antigen and methods for making and using such a plasmid are disclosed and claimed. The genospecies can be burgdorferi, garinii and/or afzelli. The antigen can be OspA and/or OspB and/or OspC. Compositions containing the plasmid DNA are useful for administration to a host susceptible to Lyme Disease for an in vivo response, such as a protective response, or for generating useful antibodies. The inventive plasmid can also be transfected into cells for generating antigens in vitro. And, the inventive plasmid can be prepared by isolating DNA (such as DNA coding for: promoter, leader sequence, antigen, and terminator) and performing a ligation or ligations, such as a three-way ligation. More particularly, administration of DNA encoding Borrelia genospecies antigen, e.g.Type: GrantFiled: June 14, 1996Date of Patent: December 8, 1998Assignees: Pasteur Merieux Serums et Vaccins, Vical Inc., University of Texas Health Science CenterInventors: Robert C. Huebner, Jon A. Norman, Xiaowu Liang, Kristin R. Carner, Alan G. Barbour, Catherine J. Luke
-
Patent number: 5612037Abstract: Conjugates of HA protein of influenza virus suitable for formulation as a vaccine for obtaining a strong immune response to the HA protein are formed by separating whole HA protein from the influenza virus by detergent extraction or by providing whole HA protein by recombinant procedure, treating the HA protein with hydroxylamine to form free sulfhydryl groups in the cytoplasmic domain of the protein, and cross-linking the free sulfhydryl group-containing HA protein to itself using a bis-maleimide linker or to a maleimide-modified diphtheria toxoid, tetanus toxoid or influenza NP protein or other carrier molecule. The procedure is applicable to other proteins which can be separated from a cellular material, such as a virus, and which contain thioester bonds convertible to sulfhydryl groups.Type: GrantFiled: July 26, 1994Date of Patent: March 18, 1997Assignee: Connaught Laboratories, Inc.Inventors: Robert C. Huebner, Maurice W. Harmon